We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Technology Simplifies Gene Expression

By Biotechdaily staff writers
Posted on 29 Oct 2002
New technology called DACS (discriminative analysis of clone signatures) is designed to simplify functional genomics. More...
The first application is GE-DACS, to eliminate bottlenecks in the discovery process of genes expressed in tissue or in a cell.

The technology, based on EST (expressed sequence tag) sequencing, reduces cost while offering the same advantages. DACS marks only one nucleotide of the four composing DNA (A, C, G, T) and includes a capillary multiplex sequencing, thus offering high-throughput (1,536 samples per run). A patented signal analysis technology applied to sequencing results discriminates identical clones from the different ones, thus allowing the discovery of genes expressed. Unlike existing processes, DACS reduces the expense and time needed to generate resources and information for the expression analysis of genes.

DACS can speed up the discovery process and also facilitate expression analysis without the need to access data relating to the organism in question. Because it is based on the generation of complementary DNA clones, DACS ensures that these biological resources are kept intact, and a link to the information produced is established for each clone. If, during the discovery process, researchers suspect the implication of a particular gene in a disease, they can access the initial biological resource and begin an in-depth analysis.

The simplicity of the process means that experiments can be more easily reproduced. This is crucial for differential expression analysis, for example, where gene expression in a normal cell is compared to a cancerous cell. Other applications for DACS include genome sequencing finishing and structural differential genome analysis. DACS was developed by Genome express (Grenoble, France).

"GE-DACS enriches our technology portfolio with the addition of high-throughput differential expression analysis,” said Yves Laurent, CEO of Genome express. "DACS is proof of Genome express's ability to develop innovative proprietary tools linking molecular biology to bioinformatics.”




Related Links:
www.genomex.com

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.